Get started
Lufthansa Investment updateSo it has been a while since I said anything about this stock but I am still in this stock and even just added some shares a week ago. When we look at the chart we can see that the price is been going up for a little now. We see that we just hit a resistance zone and that the price was not able yet to break it at this point. The good thing is that there is a descending wedge that we nicely did break and did a retest of the wedge without breaking the wedge before the big move up. We can also see that all the MA’s are below the price what also could indicate that the price is bullish so it looks good for us for now. I am now waiting to see a break of the resistance zone next week. I will update you when it is needed. If you have any questions feel free to send me a message. If you like the idea do not forget to give it a like and feel free so share your idea on this in the comments. Everything you see on my profile is just for educational purposes only.
SWB:LHALong
by MaBaCapital2
Bayer AG (BAYN.de) bullish scenario:The technical figure Channel Down can be found in the German company Bayer AG (BAYN.de) at daily chart. Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds, and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index. The Channel Down has broken through the resistance line on 12/01/2021, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 49 days towards 54.270 EUR. Your stop loss order according to experts should be placed at 43.905 EUR if you decide to enter this position. Bayer AG on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts. Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements. The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
Bayer AG - another chance to reverse a 4 year long bearish trendDaily: - Ichimoku setup is neautral, with some bullish bias. Price attempts a bullish cloud breakout, which in case of a success would mean a break of the long term bearish trendline too. - HA price action and indicators are positive - EWO is picking up Weekly: - Ichimoku setup is turning to neutral from bearish. Price trades above weekly Kijun (26 weeks average) - A possible higher low print in Dec/2021. - Upper key levels to confirm a bullish trend reversal is around 51,15. - Weekly EWO is still negative This stock still has to do some hard work to reverse, but it must be put on your watchlist. In case it decisively broke out and reversed the trend, it would have a decebt upside target to around 80.
XETR:BAYNLong
by Kumowizard
1
no description neededno description needed no description needed no description needed no description needed no description needed no description needed no description needed no description neededno description needed no description needed no description needed no description needed no description needed no description needed no description needed no description neededno description needed no description needed no description needed no description needed no description needed no description needed no description needed no description needed
XETR:22UA
by Goku13_7
BP p.l.c stock analysis - bullish trendSwing-Trade analysis (1d chart) SMMA-Analysis & Support and Resistance: - The 100er SMMA (yellow) seems to be used as a major support line since the middle of August 2021. - Golden Cross (bullish breakout pattern): We can see how the 50 SMMA (white) cut the 200 SMMA (red) in the end of October 2021. If the 100er SMMA cuts the 200er before the 8th of February (Earnings & Revenue Disclosure), we have another strong buy signal. - The green line shows a mid-term resistance at 3,95 USD Chart-Pattern: - We see a bullish channel (thin yellow lines) - if you extend the lines to the left, you can clearly see that the channel started in November 2020. - We also see a symmetrical triangle (thin white lines) which might indicate a bullish continuation if the upper line is going to be cut; or reversal if the lower line is going to be cut. However, it seems that investors are waiting for the 8th of February, because the triangle closes in that area. Momemtum Indicators: RSI: No divergence detected. RSI moves around 50 for a while which means that the stock is neither overbought nor oversold. MACD: The histogram turns to the green zone which indicates the market is increasing in buying momentum. MACD line rises above the signal line, the indicator gives a bullish signal, which suggests that the price of the asset is likely to experience upward momentum. CVO OBV: No divergence detected. However, the histogram is above zero since the beginning of December which confirms an upward momentum. Conclusion: Based on the findings we see an upward continuation. I would place a long position before the earnings report at around 4 USD. Possible Sell-order might be at around 4,3 USD (below the annual high of 2021) or even higher. Stop-loss should be placed on the 100er SMMA. A more conservative stop-loss might be the 0.236er FIB at 3,834 USD. Last but not least, It seems that investors are waiting for February earning results, and for this reason my analysis should be taken with a grain of salt.
XETR:BPE5Long
by Cenkson
1
Long BAYER - Trading & Portfolio To evaluate XETR:BAYN share in the short term, it is necessary to make a premise on the weekly chart. The trend is bearish from 2015 until today, the stock has gone from just over 140 in the spring of 2015, to just under 40 in October 2020; today XETR:BAYN is around 47. In the weekly chart you can see several recurrences: 1) Bullish divergences between prices and indicators (February 2016 - September 2016 and December 2018 - May 2019) with subsequent price rebound of about 30-35% from the breaking of the trendline. 2) Failure of new relative highs (post bullish divergences) both in 2017 and in the V-shaped rebound occurred post lockdown Covid-19 in 2020. In the last weeks, prices are approaching the bearish trendline , after having marked a double relative low in the 44 area, without reaching the previous low in the 40 area. Given these premises, the daily chart has created several interesting movements from August 2021 until today. First of all, I point out the bullish divergence of the August-September 2021 period, which was followed by a rebound in the price of XETR:BAYN from 45 to 51 (approximately + 13%), a rebound that was "perfectly" interrupted on the trendline of the weekly chart. Subsequently, the price fell again, marking new relative lows in area 44, and then building an interesting LONG entry in the last month. In detail, I personally noticed the following patterns: 1) Tweezer Bottom Pattern created by the lower shadows of the 2 candles indicated in the circle, the second candle is also a Southern Doji (without body); this corroborates the reversal potential. 2) Cup & Handle (forced) as the second corner is very wide, and is more like a double low. However, overall the pattern indicates further reversal potential; as the price did not hit new lows below 44. 3) Currently the price is inside the resistance zone created by the previous gap. That zone was breached intraday, but not with daily candles, so in my view it is somewhat intact but less "strong". Given these analyzes, several LONG strategies could be constructed. In the short term (very short), a strategy could be set up with the following values: - Entry price: 47.00 (current value) - Stop Loss: 45.70 (approximately -2.7%) -> value taken from the last gap - Target Price: 51.00 (approximately + 8.5%) -> value chosen for the relative maximum of November 2021 If XETR:BAYN stock will reach the value of 50.00, it could be considered to modify the stop loss by bringing it above the entry price, allowing any gains to run. From a short/medium term perspective, a strategy could be set up with the following values: - Entry price: 47.00 (current value) - Stop Loss: 43.50 (approximately -7.5%) -> value below the last relative minimum of 44 - Target Price: 57.00 (approximately + 21%) -> value chosen for the relative maximum of May 2021 If XETR:BAYN stock will reach the value of 54.00 (Gap still open), it could be considered to modify the stop loss, bringing it to the 51.00 area and letting any gains run. In a long-term and portfolio construction perspective, the holding of XETR:BAYN could be evaluated, given the following considerations. COMPANY DESCRIPTION Bayer operates in the pharmaceutical chemical sector in businesses related to the improvement of the quality of life. The first sector is the pharmaceutical and the second is the agricultural, through which it supplies products that improve the quality of food. Bayer consolidates 420 companies in over 90 countries with a total of 117,000 employees. The company is very active in portfolio rationalization operations. The last significant acquisition implemented in 2018 was that of Monsanto, financed with a capital increase of EUR6bn. Geographically, Bayer achieved 35.7% of turnover in Europe, the Middle East and Africa, 29.2% in North America, 20.5% in Asia and 14.6% in Latin America. FUNDAMENTAL ANALYSIS Corporate business recovering in 2021 after 2020 affected by the pandemic. After a first half year with growing turnover and better profitability (EBIT returned to positive and net loss reduced to EUR 246 million from 8 billion in 1H20), the third quarter also improved in terms of sales (+ 14.3%) and profitability. Net profit of EUR 85 million against a loss of EUR 2.7 billion in the corresponding period of the previous year. The good results prompted the management to improve again the forecast for 2021: turnover at EUR 44 billion and EPS in the range of EUR 6.5-6.7 vs respectively 43 billion and EUR 6.4-6.6 range estimated in August . No new extraordinary costs have been allocated related to the dispute with the US Supreme Court in relation to the Roundup affair (herbicide based on glyphosate considered carcinogenic), denoting how Bayer, after the compensation plans proposed in recent years, is now more confident for a favorable sentence , expected by 2022. In this long-term context, the position is to be considered without stop loss and any entry and exit prices will be evaluated in the future, based on how the stock will behave in the coming weeks; as XETR:BAYN stock is part of the pharmaceutical sector and is therefore a "defensive" stock. Dr. Cunti Mattia, CFTe®, EFA ** WARNING ** The content of the analysis just carried out is the result of personal opinions and does not constitute a solicitation to buy or sell any financial instrument. These views therefore do not constitute advice or a recommendation to invest or disinvest. The analyzes are for informational purposes only, and do not constitute personalized advice, as the writer does not know the personal characteristics of any of the readers, especially income flows, ability to bear losses, equity consistency.
XETR:BAYNLong
by Tia_Cnt